Partnering for Oncology Development Success
At every stage of oncology development, Novotech partners with you to navigate complexity, reduce execution risk, and support successful development outcomes.
Accelerated development across all phases globally
- From first-in-human studies to registration-enabling programs
- Access to experienced oncology teams, investigators, and sites to support efficient study execution
- Global capabilities combined with strong regional expertise in key oncology research markets
Rapid navigation over complexity
- Support for complex oncology studies/programs across indications, modalities, and geographies
- Expertise in advanced study designs, biomarker-driven development, and emerging treatment modalities
- Flexible delivery models tailored to sponsor needs
Advance Globally with Confidence
- Driving rapid execution beating industry enrollment benchmarks across tumor types and phases
- Navigation of development strategy from local/regional to global span
- Deep regulatory expertise in APAC, Europe and North America
Early Development
Through ApprovalGlobal Regulatory &
Operational SupportTherapies Reaching
PatientsQuality & Compliance
at Every StepScientific Excellence
& InnovationData Integrity &
Transparency
Our Oncology Experience at a Glance
Novotech supports oncology programs across diverse indications, emerging treatment modalities, and all phases of development, from first-in-human studies through global registration-enabling trials.
~850
Oncology studies conducted
2000
Oncology investigators and key opinion leaders engaged
3475
Oncology sites activated globally
9200+
Oncology patients enrolled
~75
Oncology indications supported
~110
Biomarker-driven oncology studies*Source: Oncology Trials Biomarker Assessment 25 May 2026
~40
Countries supporting oncology programs
Our Oncology Advantage
Deep Oncology Expertise
- Dedicated oncology leadership and therapeutic expertise
- Experience across solid tumors, hematologic malignancies, and rare diseases
- Expertise in complex study designs, including biomarker-driven, adaptive, basket, and umbrella studies
- Supporting emerging modalities, including ADCs, cell therapies, gene therapies, radiopharmaceuticals, and immunotherapies
Strategic Global Access
- Deep roots in many of the world's leading oncology research markets
- Established relationships with investigators, sites, and market centers across Asia-Pacific, North America, and Europe
- Access to diverse patient populations across high-frequency and difficult-to-recruit oncology indications
- Strong presence in regions and centers driving global oncology innovation and clinical research activity
Seamless Global Delivery
- Integrated delivery model across Asia-Pacific, North America and Europe
- Global coordination and regulatory expertise supporting multinational oncology programs
- Experience supporting oncology programs from first-in-human through registration and post-marketing studies
- Track record supporting successful oncology development outcomes
Experience Across Complex Oncology Study Designs
Novotech is at the forefront of advanced trial designs, enabling innovative development models with rapid execution.
Biomarker-driven and genetically defined populations
Complex screening requirements
Adaptive and seamless phase designs
Basket and platform trials
Translational, exploratory, and correlative endpoints
Multi-regional and multi-country trial execution
Combination therapy development strategies
Decentralized and hybrid trial models
Indication Experience
Lung cancer NSCLC, SCLC
Breast cancer Triple-negative, Luminal A, Luminal B, HER2-positive
Gastrointestinal cancers Colorectal cancer, Gastric cancer, Pancreatic cancer, Esophageal cancer
Hepatobiliary cancers Hepatocellular carcinoma, Biliary tract cancer
Gynecological cancers Ovarian cancer, Endometrial carcinoma, Cervical cancer
Urogenital cancers Prostate cancer, Bladder / Urothelial cancer, Renal cancer
Skin cancer Melanoma
Head and neck cancers
Hematologic malignancies Leukemia, Lymphoma, Multiple myeloma
CNS tumors Glioblastoma
Sarcoma Osteosarcoma, Soft tissue sarcoma
Pediatric oncology Neuroblastoma, Retinoblastoma, Leukemias, Lymphomas
Rare genomic cancers
Cell and gene therapy in vivo CAR
Other cancers
Dedicated Oncology Leadership and Scientific Expertise
Our oncology specialists bring scientific, medical, and operational experience to help sponsors navigate complex development decisions and deliver oncology trials across regions and phases
